About Us

Niall Martin

Chief Executive Officer

Niall has served as Chief Executive Officer at Artios since the company’s foundation in 2016. During this time, he has raised a total of $320M, with a ground-breaking $153M Series C financing in July 2021.

Niall has over 30 years of extensive experience in both biotech and pharmaceutical industries, predominately in the DNA Damage Response (DDR) field for cancer therapeutics. Prior to joining Artios, Niall was a co-founder and Chief Operating Officer at MISSION Therapeutics, a company focused on the commercialization of expert research into ubiquitin pathways for the treatment of neurological disorders, cancers and other diseases. Before that, Niall was Head of KuDOS Pharmaceuticals (a subsidiary of AstraZeneca) delivering a number of DDR projects into AstraZeneca’s oncology pipeline after the acquisition of KuDOS for $220M. This included KuDOS’ PARP program, which resulted in the discovery and development of Lynparza™ (olaparib), the first PARP inhibitor to market.

Niall holds a PhD in Zoology from Aberdeen University.

Christine Silverstein

Chief Financial Officer

Christine has served as Chief Financial Officer at Artios since 2024.

She has more than 20 years of experience in public and private corporate strategy, business development, and financial planning. Christine is a seasoned biotechnology strategy, finance, and operations executive having led numerous capital markets transactions, from structured financing and IPOs to partnerships and M&A. Prior to joining Artios, she served as Chief Financial Officer at Excision Biotherapeutics Inc., and before that at Emendo Biotherapeutics (acquired by AnGes Inc.). Other senior roles have included Chief Financial Officer at Abeona Therapeutics and Managing Director at SCO Capital Partners, a New York-based biotechnology venture fund. Christine currently also serves on the Boards of Marinus Pharmaceuticals and Abeona Therapeutics, both focused on rare pediatric diseases.

Christine holds a BSc degree from Peter Tobin College of Business at St. John’s University and has earned accreditations from the Financial Industry Regulatory Authority (FINRA) and Harvard University.

Andrew Muncey

Chief Operating Officer and Company Secretary

Andrew has been Artios’ Chief Operating Officer since 2021. Prior to this, he was the company’s Chief Financial Officer from 2016 to 2021.

He brings over 30 years of experience in corporate finance and management to Artios. He previously served as Co-founder and Chief Financial Officer of Acacia Pharma, and Chief Executive Officer of Amura Therapeutics. He was also the Chief Financial Officer or Finance Director of several biotechnology companies, including PhoreMost, MISSION Therapeutics, Bicycle Therapeutics, Kymab, and Virttu Biologics. During this time, Andrew has raised significant amounts of equity and debt funding, including over $500 million in private equity. He has also completed many acquisitions, disposals, restructuring, and licensing deals in the healthcare market. He has over 15 years of corporate finance and capital markets experience from PricewaterhouseCoopers and UBS.

Andrew is a Fellow Chartered Accountant.

Graeme Smith

Chief Scientific Officer

Graeme has served as Chief Scientific Officer at Artios since 2017.

He has more than 30 years of experience in oncology research, with significant expertise and in-depth knowledge in the field of DNA Damage Response (DDR). He joined Artios from AstraZeneca, where he held the position of Senior Director of Bioscience within the Oncology Innovative Medicines and Early Development (IMED) division. In this role, Graeme was a member of the Oncology Research Board and led teams in the discovery and development of novel targeted anti-cancer agents. Prior to that, he was Head and Research Director at KuDOS Pharmaceuticals where he played a key role in the discovery and development of Lynparza™ (olaparib), the first targeted DDR inhibitor to reach the market.

Graeme holds a PhD from the University of Edinburgh and subsequently worked as a Research Fellow at the Wellcome/CRC Institute at the University of Cambridge in the laboratory of Professor Sir Steve Jackson, FRS.

Ian Smith

Chief Medical Officer

Ian has served as Chief Medical Officer at Artios since 2019.

He has a wealth of experience in the translational research and clinical development of medicines to treat cancer. Prior to joining Artios, Ian served as Global Senior Medical Director within Eli Lilly where he led the worldwide clinical development, regulatory approval and subsequent commercialization of key successful breakthrough medicines for multiple indications. Before that, Ian held the position of Medical Science Director of Global Oncology Medicine Development at AstraZeneca, where he led both early and late phase clinical development of several novel cancer therapeutics for both adult and paediatric indications. Prior to joining the pharmaceutical industry, Ian was a Clinical Lecturer at the University of Aberdeen where he led research projects evaluating novel methods of predicting and assessing early treatment response of cancer therapeutics. Ian has served as a reviewer for several oncology journals and sat on national grant awarding panels within the United States and the United Kingdom.

Ian holds a medical degree from the University of Aberdeen.

John Graham

VP of CMC

John has served as Vice President of Chemistry, Manufacturing & Controls (CMC) since 2022.

In his role, John is responsible for API & Drug Product development and production through to clinical trial supplies and CMC regulatory interactions. Prior to working at Artios, John served as the Vice President of CMC and Technical Operations at Destiny Pharma. Before this, he was the Director of CMC and Pharmaceutical Development at PAION UK Limited. In his 20 years in the biotech field, John has also held different pharmaceutical development roles within several companies in Pharma (Fisons, Astra Charnwood), CDMO (Quintiles) and Biotech (CeNeS Ltd and MISSION Therapeutics). In these roles, he has developed a number of new products within different therapeutic areas including injectables, oral and topical products in support of early to late-stage clinical research, some of which are now commercialized.

Johns holds a BSc degree in Pharmacy and an MSc in Pharmaceutical Analysis from the University of Strathclyde, Glasgow.

Bryony Harrop

VP of Clinical Development

Bryony has served as Vice President of Clinical Development since 2020.

Bryony is a seasoned pharmaceutical industry professional with over 20 years of experience through all stages of drug development in cutting-edge oncology clinical trials across a broad range of malignancies. She was previously Oncology Delivery Director at AstraZeneca, where she held various leadership positions in the Early Clinical Development, Global Project Management, and Global Medical Affairs units over a period of fifteen years. Before AstraZeneca, Bryony worked at Eisai and at contract research organizations such as MDS Harris and Chiltern International Limited, and in the NHS at Northampton Community Healthcare Trust.

Bryony holds a BSc in Biochemistry and Biological Chemistry from the University of Nottingham.

Desiree Headley

VP of Clinical Science

Desiree has served as Vice President of Clinical Science since 2021.

Desiree has over 20 years of pharmaceutical experience working in various functions across oncology research & development in a wide range of cancer indications. Most recently, she worked at GSK as a Cell and Gene Therapy Specialist overseeing investigator engagement initiatives and study oversight for multiple phase I/II trials. Prior to that, Desiree worked at AstraZeneca and Eli Lilly as a medical scientist responsible for the medical oversight and conduct of small and large phase II and III clinical trials. Desiree’s vast experience in late-stage oncology clinical development also includes regulatory submissions and approvals and working with product launch and commercialization teams.

Desiree has a BSc in Health Science from Eastern University and an MSc in Clinical Research from George Washington University.

Robert Heald

VP of Chemistry

Robert has served as Vice President of Chemistry since 2016.

Rob is a seasoned medicinal chemist and drug discovery expert with over 20 years of industrial experience. Before joining Artios, Rob was the Head of Chemistry at Akesios Therapeutics. Prior to this, Rob served as the Director of Chemistry at Argenta Discovery (latterly Charles River) where he managed a group of over 30 chemists and led teams and projects in collaboration with a wide range of institutions, from universities to large biotech and Pharma. These collaborations included 10 years with Genentech and 5 years with Chiesi. During this time, his teams were responsible for the discovery of 6 clinical candidates for oncology and respiratory indications, the most advanced of which is now in Phase III clinical studies. Rob is also an author or inventor of over 50 publications and patents.

Rob holds a BSc in Chemistry and a PhD in Anti-Cancer Drug Design and Synthesis from the University of Nottingham

Gillian Langford

VP of Clinical Development

Gillian has served as Vice President of Clinical Development since 2019.

Gillian has over 25 years of research and development experience in both pharmaceutical and biotechnology companies. Before Artios, Gillian was at Bicycle Therapeutics where she was part of the leadership team and was VP of Clinical and Project Management responsible for moving Bicycle’s lead compound into the clinic. Prior to this, she was Director of Programme Management at Boyd Consultants and worked with European and North American companies developing oncology products and gene-based medicines. Gillian also worked at Alizyme Therapeutics, Ark Therapeutics and Imutran Ltd, a Novartis Pharma AG company. At Ark Therapeutics, Gillian was responsible for all aspects of the company’s lead gene therapy product, including non-clinical studies, manufacturing, regulatory and clinical trials (phases II and III). At Imutran Gillian was Unit Head of Molecular Biology and subsequently as Unit Head of Retroviral research managing internal research projects and collaborations with academic groups.

Gillian graduated from Imperial College London and obtained her PhD in Molecular Biology at York University.

Helen Robinson

VP of Biology

Helen has served as Vice President of Biology since 2017.

Helen has 20 years of experience in oncology research, the majority within the DNA Damage Response (DDR) field. Since joining Artios, she has overseen the building of the DDR biology platform and continues to lead the biology department, supporting the drug discovery process from target ID and cell assay development through to identifying and validating patient selection hypotheses. Prior to Artios, Helen was at MISSION Therapeutics where she was both a team and project leader responsible for various drug discovery efforts up to the preclinical stage, leading both biomarker discovery and new targets functional teams. Before this, Helen was a Research Associate at the University of Cambridge and a Senior Scientist at KuDOS Pharmaceuticals.

Helen holds a PhD in Cancer Sciences from the University of Glasgow and a BSc in Biochemistry with Molecular Biology from the University of Leeds.

Dr Simon J. Boulton, FMedSci FRS

VP of Scientific Strategy

Simon has served as Vice President of Scientific Strategy since 2016.

Simon is also a Senior Group Leader at the Francis Crick Institute and the Director of Cancer Research UK for London. He is also an honorary Professor at University College London and Kings College London, a Fellow of the Academy of Medical Sciences (FMedSci) and a member of the European Molecular Biology Organization (EMBO). Over the last 15 years, Simon’s laboratory has discovered novel DNA repair genes and provided molecular insights into their impact on human diseases. As a result of his ground-breaking work, Simon has received a number of prestigious accolades, most notably the EMBO Gold Medal and the Paul Marks Prize for Cancer Research. He has also given numerous prize lectures, including the Royal Society Francis Crick Prize lecture and the Mendel Lecture. Simon previously established the DNA Damage Response Laboratory at Cancer Research UK, London Research Institute, Clare Hall Laboratory.

Simon received a PhD in Molecular Biology from the University of Cambridge and has completed post-doctoral fellowships at Harvard Medical School, Boston.

Dr Stephen V. Frye

Scientific Advisor

Stephen is currently the Fred Eshelman Distinguished Professor and Director of the Center for Integrative Chemical Biology and Drug Discovery in the Division of Chemical Biology and Medicinal Chemistry at the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.

Stephen has a broad background in drug discovery and development, and most notably, he was responsible for co-inventing the marketed product Avodart and created the department that discovered the FDA-approved kinase inhibitor oncology therapies Lapatinib (Tyverb®) and Pazopanib (Votrient®), while at GlaxoSmithKline (GSK). Previously, Stephen was VP of Discovery Medicinal Chemistry at GSK. Stephen is currently Chair of Cancer Research UK’s Drug Discovery Committee, Member of A*STAR Project Review Committee of the Experimental Therapeutics Center in Singapore, Co-Founder and Vice President of the Academic Drug Discovery Consortium and Member of the SAB for the Spanish National Cancer Research Centre/ Experimental Therapeutics Programme.

Stephen received a PhD in Organic Chemistry from UNC Chapel Hill in the US.

Professor Geoff Higgins

Scientific Advisor

Professor Higgins is a CRUK Clinician Scientist within the CRUK/MRC Oxford Institute for Radiation Oncology and an Honorary Consultant Clinical Oncologist specializing in the management of lung cancer at Oxford University Hospitals.

His laboratory research has focused on developing treatments that can selectively kill cancer cells when combined with radiotherapy. He previously demonstrated that disruption of POLQ induces tumor-specific radiosensitization and established the initial collaboration with Cancer Research Technology to develop inhibitors against this protein. In the clinic, he has been the Chief Investigator of three clinical trials that have successfully translated new drug treatments into patient studies. He also undertook specialty training as a Clinical Oncologist at the Edinburgh Cancer Centre and became a Fellow of the Royal College of Radiologists in 2007.

Professor Higgins holds a medical degree from Edinburgh University and a PhD from Oxford University.

Professor Chris Lord

Scientific Advisor

Professor Chris Lord is the Deputy Head of Division at the Institute of Cancer Research, Team Leader of the CRUK Gene Function Laboratory, Professor of Cancer Genomics, and Deputy Director of Breast Cancer Now Toby Robins Research Centre at the ICR, London.

Much of his work focuses on exploiting genetic concepts such as synthetic lethality and functional genomics approaches to understand the behaviour of tumor cells. The ultimate aim of this work is to use this information to design novel ways to treat the disease.

Professor Lord carried out post-doctoral work at the CIMR, University of Cambridge, and at the ICR. He completed his PhD working on complex disease genetics at the Wellcome Trust Centre for Human Genetics, University of Oxford.

Pierre Legault

Chairman

Pierre currently serves as Chairman of the Board for Artios Pharma. He also serves as Chairman of the Board for Sitryx Therapeutics, Bicycle Therapeutics and Amolyt Pharma and is on the Board of Directors at Syndax Pharmaceuticals.

Pierre is a highly accomplished leader in the global biopharmaceutical industry with over 35 years of experience leading companies through high phases of growth to deliver significant shareholder value. In the past, he was a member of the Board of Directors at Armo Biosciences, Tobira Therapeutics, NPS Pharmaceuticals, Urovant Sciences Forest Laboratories, Regado Biosciences, Poxel SA Biopharmaceutical, lroko Pharmaceuticals, and Cyclacel Pharmaceuticals. Pierre also served as Chairman and CEO at NephroGenex, a biotechnology company focused on kidney diseases. Prior to this, he served as the President and Chief Executive Officer of Prosidion Ltd., which specialized in the treatment of diabetes and obesity. Before this, he was the Executive Vice President, Chief Financial Officer and Treasurer of OSI Pharmaceuticals. Mr. Legault also served as the President of Eckerd Pharmacy and Senior Executive Vice – President of Rite Aid Corporation. Prior to this, he held various roles, such as President, CEO and Chief Financial Officer, at legacy companies of the Sanofi – Aventis group.

Pierre holds an MBA in Marketing from McGill University and a Bachelor’s degree from HEC (France). He also studied at Harvard Business School. He holds an MBA, BAA, CA, CPA and Six Sigma Green Belt diplomas.

Niall Martin

Chief Executive Officer

Niall has served as Chief Executive Officer at Artios since the company’s foundation in 2016. During this time, he has raised a total of $320M, with a ground-breaking $153M Series C financing in July 2021.

Niall has over 30 years of extensive experience in both biotech and pharmaceutical industries, predominately in the DNA Damage Response (DDR) field for cancer therapeutics. Prior to joining Artios, Niall was a co-founder and Chief Operating Officer at MISSION Therapeutics, a company focused on the commercialization of expert research into ubiquitin pathways for the treatment of neurological disorders, cancers and other diseases. Before that, Niall was Head of KuDOS Pharmaceuticals (a subsidiary of AstraZeneca) delivering a number of DDR projects into AstraZeneca’s oncology pipeline after the acquisition of KuDOS for $220M. This included KuDOS’ PARP program, which resulted in the discovery and development of Lynparza™ (olaparib), the first PARP inhibitor to market.

Niall holds a PhD in Zoology from Aberdeen University.

Nora Brennan

Chair of the Audit Committee

Nora Brennan is currently the Chief Financial Officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies guided by functional genomics. She also serves as a Director and Audit Chair at Spectrum Pharmaceuticals, Inc.

Nora has served on management teams of publicly traded life science companies for the past 15 years, raising more than $2 billion in capital, building finance organizations and supporting operations from early development stage into commercialization. Prior to Fore, she was the Chief Financial Officer of TELA Bio, Inc., where she guided the company through a successful IPO and follow-on financing. Previously, Ms. Brennan spent 11 years as the Senior Vice President of Treasury and Investor Relations at Integra LifeSciences Holdings Corporation, where she served in numerous capacities and led Integra through a myriad of financings. She was key to the capital markets strategy over a significant period of time and successfully integrated 18 acquisitions leading to significant revenue growth for the company.

Nora received a BA in Economics from the University of Illinois at Urbana-Champaign and an MBA from the University of Chicago Booth School of Business.

Irena Melnikova

Director

Irena Melnikova, is a Partner at Pfizer Ventures and serves as a board director of Priovant Therapeutics, Crossbow Therapeutics, Flare Therapeutics and Telavant Holdings.

Irena is an accomplished biopharma and finance executive with over 20 years of experience in equity financings in both public and private markets, corporate strategy, business development, and operations. Prior to Pfizer Ventures, she served as the Chief Financial Officer at Umoja Biopharma where she was a senior member of the executive team responsible for all aspects of financial strategy and operations of the company. Prior to Umoja, Irena was a Managing Director, Biopharma Investment Banking at SVB Leerink, where she provided critical advice to biopharma companies and their boards on equity financing strategies, completing over 80 transactions raising over $9 billion for clients. Earlier in her career, she held leadership positions at Sanofi and TVM Capital.

Irena received a PhD in Molecular Medicine/Molecular Biology from the University of Texas Health Science Center at San Antonio.

Chris Liu

Director

Chris Liu currently serves as a Senior Research Analyst at RTW where he leads oncology research on biotechnology companies and covers life sciences companies in China.

Chris brings over 10 years of financial and biotechnology experience, specializing in oncology therapeutics across diverse indications, technology platforms and stages of development. Prior to joining RTW, Chris spent 5 years in Business Development at GenScript, where his work focused on antibody drug discovery and development including novel immuno-oncology targets. He also helped design and optimize chimeric antigen receptor (CAR) constructs for CAR-T cell therapy companies such as Kite, Juno, and Bellicum.

Chris received a PhD in Biochemistry from SUNY Stony Brook University and a BSc in Chemistry from Fudan University. He also received his MBA in Finance and Management from NYU Stern School of Business.

Michelle Doig

Director

Michelle Doig is a Partner and Head of Corporate Development at Omega Funds. She is currently serving as a Director and President of Omega Alpha SPAC.

Michelle has over 20 years of experience working with life sciences companies at leading international venture capital and investment banking firms. Prior to joining Omega, she was Director of Corporate Finance at Third Rock Ventures where she supported numerous portfolio companies. Before this, Michelle was a Principal, Corporate Finance at Abingworth. Michelle began her career as a life sciences investment banker with multiple investment firms, including Morgan Stanley (Toronto and New York), JPM H&Q (New York and San Francisco) and Lehman Brothers (London, UK).

Michelle holds an HBA in Business Administration from the Richard Ivey School of Business at Western University, London, Ontario.

John Hohneker

Director

John Hohneker, M.D., brings over 30 years of extensive experience in drug development and leadership across the biotech and pharmaceutical sectors. He most recently served as President and Chief Executive Officer of Anokion SA. Prior to this, he held the role of President of Research and Development at FORMA Therapeutics Inc. Before joining FORMA Therapeutics, Dr. Hohneker held roles of increasing responsibility at Novartis AG, including most recently as Senior Vice President and Global Head of Development, Immunology, and Dermatology.

Dr. Hohneker currently serves on the Board of Directors of Arrivent Biopharma, Carisma Therapeutics, Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics, Inc. Dr. Hohneker received his bachelor’s degree in chemistry from Gettysburg College and his M.D. from the Rutgers School of Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey-Rutgers Medical School).

René Kuijten

Director

René Kuijten is Head of EQT Life Sciences and Partner at EQT. He is also Vice Chairman of the Supervisory Board of Oncode Institute which he co-founded, and he advises the Dutch government on life sciences policies through HealthHolland.

René was Managing Partner at LSP from 2001 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Prior to LSP, René was senior consultant for 8 years at McKinsey & Company and co-leader of their European Healthcare Practice. Furthermore, he served on the board of the Dutch Private Equity and Venture Capital Association (NVP) for 12 years.

René obtained his MD from Utrecht University; his PhD from the University of Amsterdam on research performed as a WHO fellow at the University of Pennsylvania. He also obtained an MBA from INSEAD in Fontainebleau.

Nikola Trbovic

Director

Nikola is a Partner at SV Health Investors in the Biotech team.

Previously, Nikola was a Partner at Pfizer Ventures, Pfizer’s corporate venture capital group. There he was responsible for investments in emerging companies developing transformative medicines spanning all therapeutic areas and modalities aligned with the future directions of Pfizer. In prior roles at Pfizer, Nikola held responsibilities for R&D technology investments, R&D strategy and early clinical portfolio management within the R&D organization. Nikola joined Pfizer from McKinsey & Co., where he served as an Associate Principal and senior member of the Pharmaceuticals Practice, advising top pharmaceutical, biotech, and healthcare companies on a range of strategy, corporate finance and commercial topics across geographies and therapeutic areas.

Nikola has a PhD in Biochemistry and Molecular Biophysics from Columbia University and a Diploma in Biochemistry from Goethe University Frankfurt.

Samantha Truex

Director

Samantha Truex was the founding CEO of Upstream Bio. She is also on the boards of Thayer School of Engineering at Dartmouth and Life Science Cares. Sam has served in leadership roles at multiple venture-backed companies, including as CEO of Quench Bio, COO of Synlogic, and CBO for Padlock Therapeutics. Previously, she was Vice President of Corporate Development at Biogen where she led transactional business development activities and served as program executive for now-marketed products FAMPYRA,® ELOCTATE™ and ALPROLIX™. Sam also previously worked in Corporate Development at Genzyme, Chiron Diagnostics and Health Advances.

Sam earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth and an MBA from the Tuck School at Dartmouth.

Raphael Wisniewski

Director

Raphaël is a Partner on the Life Sciences Team at Andera Partners (formerly Edmond de Rothschild Investment Partners). Raphaël is also on the Board of Directors at Axonics, Poxel, ReViral, MedDay and Grey Wolf.

Previously, he worked in Healthcare Corporate Finance at Goldman Sachs and before this he was an analyst at Salomon Smith Barney. He worked in the Finance Department of Health in London and in the finance department of General Healthcare in London, the private hospital group.

Raphaël holds a postgraduate diploma in Economics and Finance from the Institut d’Etudes Politiques (IEP), Paris and is a graduate of the Ecole des Hautes Etudes Commerciales.

Chen Yu

Director

Dr. Yu is the founder and Managing Partner at TCG X. Prior to founding TCG X, Dr. Yu was a Managing Partner for seventeen years at Vivo Capital where he pioneered the firm’s efforts in cross border investments between the US and China.

Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including his time as COO of Sagent Pharmaceuticals and CBO of China KangHui, both of which went public and were ultimately acquired. Dr. Yu also serves on the California Leadership Council for the Nature Conservancy and was previously a member of the Stanford Medical School Alumni Board of Governors.

Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.

Hakan Goker

Observer

Hakan is a Senior Investment Director at Merck Ventures, the corporate venture arm of the biopharmaceutical division of Merck KGaA, having joined the company in 2013. Previously, he was a partner at Aescap Venture in Amsterdam and prior to that at Atlas Venture in London.

Hakan has global investment and deal flow experience, and was instrumental in the creation, financing and development of business and R&D strategies for various companies including Orphazyme-DK, f-Star NL, Protaffin- Austria/UK, Bicycle Therapeutics -UK, Nimbus Discovery -US, Lumavita -CH, Nitec now Horizon Pharma -CH/US, and Egalet -DK. He is currently a board member of Asceneuron, Forendo Pharma, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.

Hakan gained his PhD in oncology from the Institute of Cancer Research/University of London, UK and was post-doctoral fellow at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital.

Lisa Patel

Observer

Lisa is a partner in the LS Team at IP Group and sits on several portfolio groups. With 10 years’ experience at GSK, starting at SB in product lifecycle, and post merger into the CV CEDD where she led programs from target ID to candidate and beyond. Lisa had responsibility for strategic initiatives in 7TMs and NRs and led, and was part of, several candidate selections during this time.

Latterly she was in CPDM, reporting to Barbara Weber and then Perry Nisen with responsibility for translational medicine support for programs in the autoimmune/inflammatory and CV space. Lisa joined an IP Group company, Modern Biosciences in 2007, and since 2008 has been its sole employee, leading the development of its main project from lab hit to a recent PoC in RA. The company was rebranded 2 years ago to Istesso and is currently valued at £140m.

She has a PhD in Molecular Genetics and an MBA.